Atrinsic (PTIX)
(Delayed Data from NSDQ)
$3.04 USD
+0.35 (12.83%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.04 +0.01 (0.16%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PTIX 3.04 +0.35(12.83%)
Will PTIX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTIX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for PTIX
Protagenic Therapeutics (PTIX) Secures Japanese Patent for Epilepsy Treatment
Protagenic Therapeutics granted new patent in Japan for modified stilbenoid
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid ...
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Protagenic Therapeutics Announces Share Purchase Rights Distribution